New cancer drug targets Hard-to-Treat tumors in first human trial

NCT ID NCT06515613

Summary

This early-stage trial is testing a new drug called CTIM-76 for people with advanced ovarian, testicular, or endometrial cancers that have stopped responding to standard treatments. The study will enroll 80 participants to determine safe dosage levels and see if the drug helps control cancer growth. Researchers are looking at how the body handles the drug and whether it causes tumors to shrink.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Duke Cancer Institute

    RECRUITING

    Durham, North Carolina, 27710, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fox Chase Cancer Center

    RECRUITING

    Philadelphia, Pennsylvania, 19111, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Gabrail Cancer Center

    WITHDRAWN

    Canton, Ohio, 44718, United States

  • John Theurer Cancer Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10021, United States

    Contact Email: •••••@•••••

  • Precision NextGen Oncology & Research Center

    WITHDRAWN

    Beverly Hills, California, 90212, United States

  • Providence Cancer Institute of Oregon

    RECRUITING

    Portland, Oregon, 97213, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • SCRI at Denver Health

    RECRUITING

    Denver, Colorado, 80218, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • SCRI at Mary Crowley

    RECRUITING

    Dallas, Texas, 75230, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Arkansas Winthrop P. Rockefeller Cancer Institute

    RECRUITING

    Little Rock, Arkansas, 72205, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Vanderbilt-Ingram Cancer Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Women & Infants Hospital of Rhode Island

    RECRUITING

    Providence, Rhode Island, 02905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.